Literature DB >> 33618763

Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.

Atsuhito Uneda1,2, Kazuhiko Kurozumi3,4, Atsushi Fujimura5,6, Kentaro Fujii1, Joji Ishida1, Yosuke Shimazu1, Yoshihiro Otani1, Yusuke Tomita1, Yasuhiko Hattori1, Yuji Matsumoto1, Nobushige Tsuboi1, Keigo Makino1, Shuichiro Hirano1, Atsunori Kamiya2, Isao Date1.   

Abstract

Glioblastoma (GBM) is the most lethal primary brain tumor characterized by significant cellular heterogeneity, namely tumor cells, including GBM stem-like cells (GSCs) and differentiated GBM cells (DGCs), and non-tumor cells such as endothelial cells, vascular pericytes, macrophages, and other types of immune cells. GSCs are essential to drive tumor progression, whereas the biological roles of DGCs are largely unknown. In this study, we focused on the roles of DGCs in the tumor microenvironment. To this end, we extracted DGC-specific signature genes from transcriptomic profiles of matched pairs of in vitro GSC and DGC models. By evaluating the DGC signature using single cell data, we confirmed the presence of cell subpopulations emulated by in vitro culture models within a primary tumor. The DGC signature was correlated with the mesenchymal subtype and a poor prognosis in large GBM cohorts such as The Cancer Genome Atlas and Ivy Glioblastoma Atlas Project. In silico signaling pathway analysis suggested a role of DGCs in macrophage infiltration. Consistent with in silico findings, in vitro DGC models promoted macrophage migration. In vivo, coimplantation of DGCs and GSCs reduced the survival of tumor xenograft-bearing mice and increased macrophage infiltration into tumor tissue compared with transplantation of GSCs alone. DGCs exhibited a significant increase in YAP/TAZ/TEAD activity compared with GSCs. CCN1, a transcriptional target of YAP/TAZ, was selected from the DGC signature as a candidate secreted protein involved in macrophage recruitment. In fact, CCN1 was secreted abundantly from DGCs, but not GSCs. DGCs promoted macrophage migration in vitro and macrophage infiltration into tumor tissue in vivo through secretion of CCN1. Collectively, these results demonstrate that DGCs contribute to GSC-dependent tumor progression by shaping a mesenchymal microenvironment via CCN1-mediated macrophage infiltration. This study provides new insight into the complex GBM microenvironment consisting of heterogeneous cells.

Entities:  

Keywords:  CCN1; Differentiated glioblastoma cell; Glioblastoma; Glioblastoma stem cell; Glioma; Macrophage; Mesenchymal subtype; Microenvironment; TEAD; YAP/TAZ

Year:  2021        PMID: 33618763      PMCID: PMC7898455          DOI: 10.1186/s40478-021-01124-7

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  64 in total

1.  Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Authors:  Amy Haseley; Sean Boone; Jeffrey Wojton; Lianbo Yu; Ji Young Yoo; Jianhua Yu; Kazuhiko Kurozumi; Joseph C Glorioso; Michael A Caligiuri; Balveen Kaur
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

3.  Activated macrophages in congenitally athymic "nude mice" and in lethally irradiate mice.

Authors:  C Cheers; R Waller
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

4.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

5.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

6.  Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways.

Authors:  Yusuke Tomita; Kazuhiko Kurozumi; Ji Young Yoo; Kentaro Fujii; Tomotsugu Ichikawa; Yuji Matsumoto; Atsuhito Uneda; Yasuhiko Hattori; Toshihiko Shimizu; Yoshihiro Otani; Tetsuo Oka; Balveen Kaur; Isao Date
Journal:  Mol Cancer Ther       Date:  2019-05-15       Impact factor: 6.261

7.  Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma.

Authors:  Joji Ishida; Kazuhiko Kurozumi; Tomotsugu Ichikawa; Yoshihiro Otani; Manabu Onishi; Kentaro Fujii; Yosuke Shimazu; Tetsuo Oka; Toshihiko Shimizu; Isao Date
Journal:  Brain Tumor Pathol       Date:  2015-07-23       Impact factor: 3.298

8.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.

Authors:  Fa-Xing Yu; Bin Zhao; Nattapon Panupinthu; Jenna L Jewell; Ian Lian; Lloyd H Wang; Jiagang Zhao; Haixin Yuan; Karen Tumaneng; Hairi Li; Xiang-Dong Fu; Gordon B Mills; Kun-Liang Guan
Journal:  Cell       Date:  2012-08-02       Impact factor: 41.582

View more
  9 in total

Review 1.  Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.

Authors:  Yoshihiro Otani; Ji Young Yoo; Toshihiko Shimizu; Kazuhiko Kurozumi; Isao Date; Balveen Kaur
Journal:  Brain Tumor Pathol       Date:  2022-04-06       Impact factor: 3.298

Review 2.  Signal Pathways Involved in the Interaction Between Tumor-Associated Macrophages/TAMs and Glioblastoma Cells.

Authors:  Xiaojin Liu; Yuan Liu; Yiwei Qi; Yimin Huang; Feng Hu; Fangyong Dong; Kai Shu; Ting Lei
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  The Anti-Tumor Efficacy of Verbascoside on Ovarian Cancer via Facilitating CCN1-AKT/NF-κB Pathway-Mediated M1 Macrophage Polarization.

Authors:  Yu Ren; Jinying He; Wenhua Zhao; Yuzhen Ma
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors.

Authors:  Omkar Singh; Drew Pratt; Kenneth Aldape
Journal:  Acta Neuropathol Commun       Date:  2021-09-08       Impact factor: 7.801

5.  Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.

Authors:  Amanda de Andrade Costa; Jit Chatterjee; Olivia Cobb; Elizabeth Cordell; Astoria Chao; Suzanne Schaeffer; Andrea Goldstein; Sonika Dahiya; David H Gutmann
Journal:  Neurooncol Adv       Date:  2021-12-31

Review 6.  Molecular Mechanisms and Clinical Challenges of Glioma Invasion.

Authors:  Tomoya Oishi; Shinichiro Koizumi; Kazuhiko Kurozumi
Journal:  Brain Sci       Date:  2022-02-20

7.  Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: Cognitive impairment and aging-related hypoxic stress.

Authors:  Weiwei Lin; Qiangwei Wang; Yisheng Chen; Ning Wang; Qingbin Ni; Chunhua Qi; Qian Wang; Yongjian Zhu
Journal:  Front Aging Neurosci       Date:  2022-09-01       Impact factor: 5.702

8.  Construction and validation of an angiogenesis-related gene expression signature associated with clinical outcome and tumor immune microenvironment in glioma.

Authors:  Tianhao Hu; Yutao Wang; Xiaoliang Wang; Run Wang; Yifu Song; Li Zhang; Sheng Han
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

9.  A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy.

Authors:  Ryo Mizuta; Yoshihiro Otani; Kentaro Fujii; Atsuhito Uneda; Joji Ishida; Takehiro Tanaka; Shuntaro Ikegawa; Nobuharu Fujii; Yoshinobu Maeda; Isao Date
Journal:  NMC Case Rep J       Date:  2022-09-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.